Danaher stock kpis
Want to see DHR full AI Analyst Report?
Recurring Revenue
Measures the portion of revenue expected to continue in the future, indicating business stability and potential for sustained growth.
Recurring revenue has moved from a mid‑$4B base into a steadier ~$5B run rate with clear multi‑year growth and stronger momentum through 2025–H1‑2026; however, quarter‑to‑quarter spikes and the pronounced year‑end troughs reflect timing/seasonality (respiratory testing swings) and bioprocessing shipment timing rather than a loss of underlying demand. Management’s M&A (Masimo closed, StatLab pending) and strong FCF support durable recurring mix expansion and buybacks, but expect lumpy quarterly cadence even as core recurring growth remains intact.
DHR Recurring Revenue
| Date | Recurring Revenue |
|---|---|
| Sep 30, 2026 | $5.40B |
| Jun 30, 2026 | $5.20B |
| Mar 31, 2026 | $5.03B |
| Dec 31, 2025 | $5.32B |
| Sep 30, 2025 | $5.02B |
| Jun 30, 2025 | $4.97B |
| Mar 31, 2025 | $4.82B |
| Dec 31, 2024 | $5.11B |
| Sep 30, 2024 | $4.78B |
| Jun 30, 2024 | $4.69B |
| Mar 31, 2024 | $4.79B |
| Dec 31, 2023 | $2.78B |
| Sep 30, 2023 | $5.18B |
| Jun 30, 2023 | $5.34B |
| Mar 31, 2023 | $5.39B |
| Dec 31, 2022 | $3.26B |
| Sep 30, 2022 | $5.83B |
| Jun 30, 2022 | $5.89B |
| Mar 31, 2022 | $5.90B |
| Dec 31, 2021 | $5.98B |
| Sep 30, 2021 | $5.42B |
| Jun 30, 2021 | $5.32B |
| Mar 31, 2021 | $5.08B |
| Dec 31, 2020 | $4.73B |
| Sep 30, 2020 | $4.23B |
| Jun 30, 2020 | $3.81B |
| Mar 31, 2020 | $3.21B |
| Dec 31, 2019 | $1.74B |
| Sep 30, 2019 | $3.50B |
| Jun 30, 2019 | $3.61B |
| Mar 31, 2019 | $3.46B |
| Dec 31, 2018 | $1.52B |
| Sep 30, 2018 | $3.35B |
| Jun 30, 2018 | $3.49B |
| Mar 31, 2018 | $3.32B |

